Ronald Chow1, Keyue Ding2, Vithusha Ganesh1, Ralph M Meyer3, Yvette M van der Linden4, Daniel Roos5, William F Hartsell6, Peter Hoskin7, Jackson S Y Wu8, Abdenour Nabid9, Manouk van Acht10, Rinus Wanders11, Scott Babington12, William F Demas13, Carolyn F Wilson2, Rebecca K S Wong14, Michael Brundage15, Liting Zhu2, Edward Chow16. 1. Sunnybrook Odette Cancer Centre, University of Toronto, Canada. 2. Canadian Cancer Trials Group, Cancer Research Institute, Queen's University, Kingston, Canada. 3. Juravinski Hospital and Cancer Centre and McMaster University, Hamilton, Canada. 4. Leiden University Medical Centre, Leiden and Radiotherapy Institute Friesland, Leeuwarden, Netherlands. 5. Royal Adelaide Hospital, University of Adelaide, Australia. 6. Northwestern Medicine Central DuPage Hospital, Warrenville, USA. 7. Mount Vernon Hospital Cancer Centre, Middlesex, United Kingdom. 8. Tom Baker Cancer Centre, University of Calgary, Canada. 9. Centre Hospitalier Universitaire de Sherbrooke, Canada. 10. Erasmus MC, Rotterdam, Netherlands. 11. MAASTRO Clinic, Maastricht, Netherlands. 12. Christchurch Hospital, New Zealand. 13. Akron City Hospital, Northeast Ohio Medical University, USA. 14. Princess Margaret Cancer Centre, Radiation Medicine Program, Ontario Cancer Institute, University of Toronto, Canada. 15. Queen's University, Kingston, Canada. 16. Sunnybrook Odette Cancer Centre, University of Toronto, Canada. Electronic address: edward.chow@sunnybrook.ca.
Abstract
BACKGROUND AND PURPOSE: Patient's gender and age may influence physicians in prescribing palliative radiotherapy. The purpose of this secondary analysis of the National Cancer Institute of Canada Clinical Trials Group Symptom Control Trial SC.20 was to explore the gender and age differences in pain and patient reported outcomes in cancer patients with bone metastases undergoing re-irradiation. MATERIALS AND METHODS: Response to radiation was evaluated using the International Bone Metastases Consensus Endpoint Definitions. Patients completed the Brief Pain Inventory (BPI) and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (C30) before and 2 months after re-irradiation. RESULTS:A total of 847 patients were analyzed. At baseline, men had more dyspnea, and mild pain. Older patients consumed less analgesic. More women reported clinically significant improvement in mood and enjoyment of life in the BPI after radiation. Similarly, younger patients reported better improvement in enjoyment of life. There were no significant gender or age differences in overall survival, response to radiation, or in C30 scores at 2 months. CONCLUSION: Similar benefit in terms of pain relief was observed across all patient groups. Cancer patients with bone metastases should be offered palliative re-irradiation irrespective of gender or age. TRIAL REGISTRATION: NCT00080912; https://clinicaltrials.gov/ct2/show/NCT00080912.
RCT Entities:
BACKGROUND AND PURPOSE:Patient's gender and age may influence physicians in prescribing palliative radiotherapy. The purpose of this secondary analysis of the National Cancer Institute of Canada Clinical Trials Group Symptom Control Trial SC.20 was to explore the gender and age differences in pain and patient reported outcomes in cancerpatients with bone metastases undergoing re-irradiation. MATERIALS AND METHODS: Response to radiation was evaluated using the International Bone Metastases Consensus Endpoint Definitions. Patients completed the Brief Pain Inventory (BPI) and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (C30) before and 2 months after re-irradiation. RESULTS: A total of 847 patients were analyzed. At baseline, men had more dyspnea, and mild pain. Older patients consumed less analgesic. More women reported clinically significant improvement in mood and enjoyment of life in the BPI after radiation. Similarly, younger patients reported better improvement in enjoyment of life. There were no significant gender or age differences in overall survival, response to radiation, or in C30 scores at 2 months. CONCLUSION: Similar benefit in terms of pain relief was observed across all patient groups. Cancerpatients with bone metastases should be offered palliative re-irradiation irrespective of gender or age. TRIAL REGISTRATION: NCT00080912; https://clinicaltrials.gov/ct2/show/NCT00080912.